Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA

Lees, Andrew J ORCID: 0000-0002-2476-4385, Ferreira, Joaquim, Rascol, Olivier, Reichmann, Heinz, Stocchi, Fabrizio, Tolosa, Eduardo and Poewe, Werner (2017) Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. EXPERT REVIEW OF NEUROTHERAPEUTICS, 17 (7). pp. 649-659.

Text Opicapone fo the management of end of dose motor fluctuations.docx - Author Accepted Manuscript Download (133kB)

Abstract

<h4>Introduction</h4>Opicapone is a third generation, highly potent and effective catechol O‑methyltransferase (COMT) inhibitor that optimizes the pharmacokinetics and bioavailability of L-DOPA therapy. Areas covered: In this review, the authors describe the preclinical and clinical development of opicapone. In PD patients with motor fluctuations, once daily opicapone administration was well-tolerated and consistently reduced OFF-time and increased ON-time without increasing the frequency of troublesome dyskinesia, and these benefits were maintained over at least a year of continued open-label therapy. Expert commentary: With its convenient once-daily regimen, adjunct opicapone should be considered as an effective option for use in L-DOPA treated PD patients experiencing motor fluctuations.

Item Type:	Article
Additional Information:	publicationstatus: accepted
Uncontrolled Keywords:	Opicapone, L-DOPA, Parkinson's disease, wearing-off, motor fluctuations, COMT inhibition
Depositing User:	Symplectic Admin
Date Deposited:	16 Mar 2018 14:42
Last Modified:	19 Jan 2023 06:38
DOI:	10.1080/14737175.2017.1336086
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3019111